Compare Neurocrine Biosciences Inc (NBIX) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Snap Inc — how do they compare? Neurocrine Biosciences Inc trades at $155.7 (market cap $15.77B), while Snap Inc trades at $5.3 (market cap $8.98B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SNAP | |
|---|---|---|
Market Cap | $15.77B | $8.98B |
Sector | Health | Media |
52-Week High | $185.50 | $9.09 |
52-Week Low | $123.10 | $3.93 |
Enterprise Value | $15.78B | $10.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
Snap Inc. (SNAP) trades at $5.43, down 0.73% on the day, with a bullish technical signal driven by moving averages and strong operational cash flow growth. The company reported a net loss of $460.49 million in 2025, but revenue grew to $5.93 billion and losses are narrowing year-over-year. Recent news includes the appointment of a new Chief Commercial Officer and ongoing legal challenges related to youth safety.
The outlook remains cautious; while improving financials and a $7.02 analyst price target suggest upside, persistent net losses, high debt, and regulatory lawsuits pose significant risks. Investor sentiment is mixed amid insider selling and legal overhangs, requiring careful risk assessment for potential investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
